Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04238819 · ClinicalTrials.gov registry record · Phase 1
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04238819 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 47 participants.
The verdict
NCT04238819, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.
Interventions
- DRUG Temozolomide
- DRUG Abemaciclib
- DRUG Irinotecan
- DRUG GM-CSF
- DRUG Dinutuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2025-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04238819
The ClinicalTrials.gov registry entry for NCT04238819 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Temozolomide is the first listed.
NCT04238819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04238819 about?
NCT04238819 is a clinical study titled "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma". The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each partici...
What is the current status of trial NCT04238819?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2020-11-09. Estimated completion is 2025-08-19.
What interventions are being tested in trial NCT04238819?
The interventions under investigation include: Temozolomide (DRUG), Abemaciclib (DRUG), Irinotecan (DRUG), GM-CSF (DRUG), Dinutuximab (DRUG).
Who is sponsoring clinical trial NCT04238819?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.